Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02763319 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 453
- Enrollment target
NCT02763319 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 453 participants.
The verdict
NCT02763319, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 453 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Interventions
- DRUG Tafasitamab
- DRUG Rituximab (RTX)
- DRUG Bendamustine (BEN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 453 participants |
| Start Date | 2016-11-28 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02763319
The ClinicalTrials.gov registry entry for NCT02763319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 453 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tafasitamab is the first listed.
NCT02763319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02763319 about?
NCT02763319 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
What is the current status of trial NCT02763319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 453 participants. The study started on 2016-11-28. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT02763319?
The interventions under investigation include: Tafasitamab (DRUG), Rituximab (RTX) (DRUG), Bendamustine (BEN) (DRUG).
Who is sponsoring clinical trial NCT02763319?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.